Advanced search
Publication Cover
Drug and Chemical Toxicology Volume 45, 2022 - Issue 1
Submit an article Journal homepage
447
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1

Andrew Lebera Landos Biopharma Inc, Blacksburg, VA, USA;b BioTherapeutics Inc, Blacksburg, VA, USA
,
Raquel Hontecillasa Landos Biopharma Inc, Blacksburg, VA, USA;b BioTherapeutics Inc, Blacksburg, VA, USA
,
Victoria Zoccoli-Rodrigueza Landos Biopharma Inc, Blacksburg, VA, USA
,
Marion Ehrichc Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA, USA
,
Jyoti Chauhana Landos Biopharma Inc, Blacksburg, VA, USA
&
Josep Bassaganya-Rieraa Landos Biopharma Inc, Blacksburg, VA, USA;b BioTherapeutics Inc, Blacksburg, VA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8967-6012
ORCID Icon
Pages 209-214 | Received 10 Jun 2019, Accepted 29 Sep 2019, Published online: 25 Oct 2019

References

  • Barba, G., et al., 2002. Recurrent pancreatitis revealing Crohn's disease. Archives de Pédiatrie, 9(10), 1053–1055.
  • Bissel, P., et al., 2016. Exploratory studies With BT-11: a proposed orally active therapeutic for crohn's disease. International Journal of Toxicology, 35(5), 521–529.
  • Braverman, I.M., 2003. Skin signs of gastrointestinal disease. Gastroenterology, 124(6), 1595–1614.
  • Camilleri, M., 2003. GI clinical research 2002-2003: The year in review. Clinical Gastroenterology and Hepatology, 1(6), 415–420.
  • Charmot, D., 2012. Non-systemic drugs: a critical review. Current Pharmaceutical Design, 18(10), 1434–1445.
  • Cohen, R.D., et al., 2000. The cost of hospitalization in Crohn's disease. The American Journal of Gastroenterology, 95(2), 524–530.
  • Fyfe, M.C., 2016. Non-systemic Intestine-targeted drugs. Progress in Medicinal Chemistry, 55, 1–44.
  • Herrlinger, K.R., et al., 2013. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the entrance study. Journal of Crohn's and Colitis, 7(8), 636–643.
  • Leber, A., et al., 2017. NLRX1 regulates effector and metabolic functions of CD4+ T cells. The Journal of Immunology, 198(6), 2260–2268.
  • Leber, A., et al., 2018. Activation of LANCL2 by BT-11 ameliorates IBD by supporting regulatory T cell stability through immunometabolic mechanisms. Inflammatory Bowel Disease, 24 (9), 1978–1991.
  • Leber, A., et al., 2019a. The safety, tolerability, and pharmacokinetics profile of BT-11, an Oral, Gut-restricted lanthionine synthetase C-Like 2 agonist investigational new drug for inflammatory bowel disease: a randomized, Double-Blind, Placebo-Controlled Phase I clinical trial. Inflammatory Bowel Disease. pii: izz094. doi: https://doi.org/10.1093/ibd/izz094.
  • Leber, A., et al., 2019b. Nonclinical toxicology and toxicokinetic profile of an oral lanthionine synthetase C-Like 2 (LANCL2) agonist, BT-11. International Journal of Toxicology, 38(2), 96–109.
  • Leber, A., et al., 2019c. Activation of NLRX1 by NX-13 ameliorates IBD through immunometabolic mechanisms in CD4+ T cells. The Journal of Immunology.
  • Lichtenstein, G. R., Abreu, M., and Present, D., 2003. Recent advances in the treatment of Crohn's colitis. The center for health care education, LLC.
  • Marri, S.R., and Buchman, A.L., 2005. The education and employment status of patients with inflammatory bowel diseases. Inflammatory Bowel Diseases, 11(2), 171–177.
  • Moser, V.C., et al., 1988. Comparison of chlordimeform and carbaryl using a functional observational battery. Toxicological Sciences, 11(2), 189–206.
  • Spunt, S., et al., 2008. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age. SEER AYA Monograph. Bethesda, MD: National Cancer Institute.
  • Stenson, W.F., 1995. Interleukin-4 hyporesponsiveness in inflammatory bowel disease: immune defect or physiological response? Gastroenterology, 108(1), 284–286.
  • Zhang, Y., et al., 2010. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed, 99(3), 306–314.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.